{"id":59203,"date":"2024-02-28T05:46:20","date_gmt":"2024-02-28T05:46:20","guid":{"rendered":"https:\/\/medsname.com\/lipaglyn\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"lipaglyn","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/lipaglyn\/","title":{"rendered":"Lipaglyn"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Lipaglyn?<\/h3>\n<p style=\"margin:0;\"><strong>Lipaglyn<\/strong> este o marc\u0103 a <strong>saroglitazar<\/strong> (4 mg), un <strong>agonist dual PPAR-\u03b1\/\u03b3<\/strong> dezvoltat \u00een India (aprobat \u00een 2013). Este unic: predominant un agonist PPAR-\u03b1 (ca fibratele) cu agonism par\u021bial PPAR-\u03b3 (ca pioglitazonul). Utilizat pentru <strong>dislipidemia diabetic\u0103<\/strong> (trigliceride ridicate \u00een diabetul zaharat tip 2) \u0219i <strong>boala hepatic\u0103 gras\u0103 non-alcoolic\u0103 (NAFLD\/NASH)<\/strong> \u2014 aprobat \u00een India pentru ambele indica\u021bii. Reduce trigliceridele cu 40\u201350%, cre\u0219te HDL, scade HbA1c cu ~0,5 puncte \u0219i \u00eembun\u0103t\u0103\u021be\u0219te gr\u0103simea hepatic\u0103 \u0219i enzimele. O tablet\u0103 (4 mg) o dat\u0103 pe zi \u00eenainte de mese. Nu provoac\u0103 hipoglicemie. \u00cen general, bine tolerat \u2014 tulbur\u0103ri gastrointestinale u\u0219oare, c\u00e2\u0219tig de greutate rar. <strong>Nu este un substitut pentru statine<\/strong> \u00een reducerea primar\u0103 a lipidelor. Evita\u021bi \u00een insuficien\u021b\u0103 hepatic\u0103 sever\u0103, sarcin\u0103 \u0219i hipersensibilitate cunoscut\u0103.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">Ce este Lipaglyn?<\/h2>\n<p>Lipaglyn este un medicament oral <strong>agonist dual PPAR-\u03b1\/\u03b3<\/strong> care con\u021bin <strong>saroglitazar<\/strong> (4 mg), dezvoltat de Zydus Cadila (India) \u0219i aprobat \u00een India \u00een 2013. Disponibil \u00een cutii de 30, 60, 90 sau 180 comprimate. Este prescris pentru:<\/p>\n<ul>\n<li><strong>Dislipidemie diabetic\u0103<\/strong> \u2014 trigliceride ridicate la pacien\u021bii cu diabet zaharat tip 2 care nu sunt controla\u021bi doar cu statine<\/li>\n<li><strong>Hipertrigliceridemie<\/strong> necontrolate \u00een mod adecvat de statine<\/li>\n<li><strong>Boal\u0103 hepatic\u0103 gras\u0103 non-alcoolic\u0103 (NAFLD) \u0219i steatohepatit\u0103 non-alcoolic\u0103 (NASH)<\/strong><\/li>\n<li><strong>Colangita biliar\u0103 primar\u0103 (PBC)<\/strong> \u2014 indica\u021bie recent\u0103<\/li>\n<\/ul>\n<p>Saroglitazarul este unic deoarece este primul agonist dual PPAR-\u03b1\/\u03b3 care ajunge pe pia\u021b\u0103. \u00cencerc\u0103rile anterioare (muraglitazar, tesaglitazar) au fost abandonate din cauza problemelor de siguran\u021b\u0103; profilul echilibrat al saroglitazarului (\u00een principal \u03b1, par\u021bial \u03b3) pare s\u0103 le evite.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Lipaglyn?<\/h2>\n<p>Receptorii activa\u021bi de proliferatorii peroxizomali (PPAR) sunt receptori nucleari care controleaz\u0103 expresia genelor \u00een metabolismul lipidic \u0219i glucidic. Saroglitazar activeaz\u0103 doi dintre ace\u0219tia:<\/p>\n<ul>\n<li><strong>PPAR-\u03b1 (predominant)<\/strong> \u2014 similar cu fibratele. Cre\u0219te oxidarea acizilor gra\u0219i \u00een ficat, reduce trigliceridele cu 40\u201350%, cre\u0219te u\u0219or HDL \u0219i reduce gr\u0103simea hepatic\u0103.<\/li>\n<li><strong>PPAR-\u03b3 (par\u021bial)<\/strong> \u2014 similar cu pioglitazon\u0103, dar mai slab. \u00cembun\u0103t\u0103\u021be\u0219te sensibilitatea la insulin\u0103 \u00een mu\u0219chi \u0219i \u021besutul adipos, reduc\u00e2nd HbA1c cu ~0,5 puncte procentuale.<\/li>\n<\/ul>\n<p>Efectul net este \u00eembun\u0103t\u0103\u021birea <em>at\u00e2t<\/em> profilului lipidic c\u00e2t \u0219i a controlului glicemic al dislipidemiei diabetice \u00eentr-o singur\u0103 tablet\u0103. Important, deoarece activarea PPAR-\u03b3 este doar par\u021bial\u0103, cre\u0219terea \u00een greutate \u0219i reten\u021bia de lichide observate cu pioglitazon\u0103 sunt mult mai pu\u021bin frecvente.<\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i administrare<\/h2>\n<p><strong>Doza standard:<\/strong> o tablet\u0103 de 4 mg o dat\u0103 pe zi, aproximativ o or\u0103 \u00eenainte de mese (diminea\u021ba).<\/p>\n<ul>\n<li>Se recomand\u0103 administrarea zilnic\u0103 la aceea\u0219i or\u0103.<\/li>\n<li>Efectele asupra trigliceridelor se observ\u0103 \u00een 2\u20134 s\u0103pt\u0103m\u00e2ni; efectul maxim asupra lipidelor la 12 s\u0103pt\u0103m\u00e2ni. Sc\u0103derea HbA1c se produce \u00een 12\u201324 de s\u0103pt\u0103m\u00e2ni.<\/li>\n<li>Dac\u0103 uita\u021bi o doz\u0103 \u2014 omite\u021bi-o \u0219i lua\u021bi urm\u0103toarea la ora obi\u0219nuit\u0103.<\/li>\n<li>Nu este necesar\u0103 ajustarea standard a dozei \u00een insuficien\u021ba renal\u0103 u\u0219oar\u0103 p\u00e2n\u0103 la moderat\u0103; folosi\u021bi cu precau\u021bie \u00een insuficien\u021b\u0103 renal\u0103 sever\u0103.<\/li>\n<li>Evita\u021bi \u00een insuficien\u021b\u0103 hepatic\u0103 sever\u0103; verifica\u021bi enzimele hepatice la ini\u021biere \u0219i periodic.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p>Saroglitazar este \u00een general bine tolerat.<\/p>\n<p><strong>Frecvente:<\/strong><\/p>\n<ul>\n<li>Disconfort gastric u\u0219or, dispepsie, grea\u021b\u0103<\/li>\n<li>Astenie (oboseal\u0103 u\u0219oar\u0103)<\/li>\n<li>Dureri de cap<\/li>\n<\/ul>\n<p><strong>Mai pu\u021bin frecvente:<\/strong><\/p>\n<ul>\n<li>Cre\u0219tere u\u0219oar\u0103 a transaminazelor (de obicei legat\u0103 de doz\u0103, reversibil\u0103)<\/li>\n<li>Cre\u0219tere u\u0219oar\u0103 \u00een greutate (de obicei &lt; 1 kg; mult mai pu\u021bin dec\u00e2t cu pioglitazon\u0103)<\/li>\n<li>Edem periferic (rar, mult mai rar dec\u00e2t la pioglitazon\u0103)<\/li>\n<\/ul>\n<p>Nu exist\u0103 un semnal clar de insuficien\u021b\u0103 cardiac\u0103 sau cancer de vezic\u0103 (spre deosebire de pioglitazon\u0103). Nu exist\u0103 \u00eenc\u0103 date din studii de outcome privind riscul cardiovascular, dar studiile limitate de p\u00e2n\u0103 acum sunt lini\u0219titoare.<\/p>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Statine<\/strong> \u2014 \u00een general bine tolerat \u00een combina\u021bie; monitoriza\u021bi pentru miopatie.<\/li>\n<li><strong>Fibrate (al\u021bi agonisti PPAR-\u03b1)<\/strong> \u2014 evita\u021bi combinarea; mecanism suprapus.<\/li>\n<li><strong>Warfarin<\/strong> \u2014 poten\u021bial\u0103 modificare a INR; monitoriza\u021bi.<\/li>\n<li><strong>Insulin\u0103 \u0219i sulfoniluree<\/strong> \u2014 hipoglicemie pu\u021bin probabil\u0103 cu saroglitazar singur, dar posibil\u0103 \u00een combina\u021bie.<\/li>\n<li><strong>Sequestran\u021bi de acizi biliari<\/strong> \u2014 poate reduce absorb\u021bia; administrare separat\u0103.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cine nu ar trebui s\u0103 ia Lipaglyn?<\/h2>\n<ul>\n<li>Insuficien\u021b\u0103 hepatic\u0103 sever\u0103<\/li>\n<li>Insuficien\u021b\u0103 renal\u0103 sever\u0103<\/li>\n<li>Sarcin\u0103 \u0219i al\u0103ptare<\/li>\n<li>Copii \u2014 siguran\u021ba nu a fost stabilit\u0103<\/li>\n<li>Hipersensibilitate cunoscut\u0103 la saroglitazar sau al\u021bi agonisti PPAR<\/li>\n<li>Insuficien\u021b\u0103 cardiac\u0103 activ\u0103 \u2014 utiliza\u021bi cu precau\u021bie, de\u0219i riscul pare mai mic dec\u00e2t la pioglitazon\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>P\u0103stra\u021bi Lipaglyn sub 30\u00b0C \u00eentr-un loc uscat, \u00een blisterul original. Depozita\u021bi \u00een afara accesului copiilor.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Cum difer\u0103 saroglitazarul de pioglitazon\u0103?<\/h3>\n<p>Ambele sunt agoniste PPAR, dar cu selectivitate diferit\u0103. Pioglitazona este \u00een principal PPAR-\u03b3 (puternic sensibilizator la insulin\u0103, cre\u0219tere \u00een greutate, reten\u021bie de lichide). Saroglitazarul este \u00een principal PPAR-\u03b1 cu <em>par\u021bial<\/em> PPAR-\u03b3 (puternic hipotrigliceridemiant, moderat sensibilizant la insulin\u0103, mult mai pu\u021bin\u0103 cre\u0219tere \u00een greutate \u0219i edem). Pentru un pacient cu dislipidemie diabetic\u0103, saroglitazarul are un efect lipidic mai puternic; pentru rezisten\u021ba pur\u0103 la insulin\u0103 cu lipide normale, pioglitazonul este \u00eenc\u0103 mai frecvent utilizat.<\/p>\n<h3 class=\"wp-block-heading\">Poate Lipaglyn s\u0103 \u00eenlocuiasc\u0103 statina mea?<\/h3>\n<p>Nu \u2014 saroglitazarul \u0219i statinele \u021bintesc diferite anomalii lipidice. Statinele scad colesterolul LDL (principalul lipid aterogen); saroglitazarul scade trigliceridele \u0219i cre\u0219te HDL. La pacien\u021bii diabetici cu dislipidemie mixt\u0103, cele dou\u0103 sunt de obicei utilizate \u00eempreun\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Ajut\u0103 Lipaglyn la ficatul gras sau NASH?<\/h3>\n<p>Da \u2014 saroglitazarul are indica\u021bii aprobate pentru NAFLD\/NASH \u00een India, bazate pe datele din studiile indiene care arat\u0103 reducerea ALT, gr\u0103simea hepatic\u0103 la MRI-PDFF \u0219i \u00eembun\u0103t\u0103\u021birea markerilor de fibroz\u0103. Este unul dintre pu\u021binele tratamente orale cu aprobare reglementar\u0103 pentru NASH oriunde \u00een lume.<\/p>\n<h3 class=\"wp-block-heading\">Cauzeaz\u0103 Lipaglyn hipoglicemie?<\/h3>\n<p>Nu de la sine \u2014 saroglitazarul nu stimuleaz\u0103 eliberarea de insulin\u0103. Hipoglicemia devine o problem\u0103 doar \u00een combina\u021bie cu o sulfoniluree, meglitinid\u0103 sau insulin\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Este Lipaglyn aprobat \u00een afara Indiei?<\/h3>\n<p>Saroglitazarul este aprobat \u00een principal \u00een India, cu unele aprob\u0103ri \u00een Mexic \u0219i c\u00e2teva alte \u021b\u0103ri. Nu este \u00eenc\u0103 aprobat \u00een SUA, UE, Marea Britanie sau Australia \u2014 aceste agen\u021bii nu au finalizat evaluarea. Din punct de vedere clinic, medicamentul a fost utilizat \u00een peste 2 milioane de ani-pacient \u00een India, cu un bun profil de siguran\u021b\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Lipaglyn online?<\/h3>\n<p>Pute\u021bi comanda Lipaglyn (4 mg) de la MedsBase \u00een cutii de 30, 60, 90 sau 180 de comprimate. Livr\u0103m \u00een \u00eentreaga lume, cu ambalaj discret \u0219i stoc original certificat WHO-GMP de la produc\u0103tor.<\/p>\n<h2 class=\"wp-block-heading\">Medicamente conexe pentru diabet \u0219i lipideme<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/pioz-15\/\">Pioz 15 \u2014 Pioglitazon (agonist PPAR-\u03b3)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/jardiance-empagliflozin\/\">Jardiance \u2014 Empagliflozin\u0103 (SGLT-2, beneficii CV\/IC)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/forxiga-dapagliflozin\/\">Forxiga \u2014 Dapagliflozin\u0103 (SGLT-2, DAPA-HF)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/glycomet-sr\/\">Glycomet SR \u2014 Metformin cu eliberare prelungit\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/januvia\/\">Januvia \u2014 Sitagliptin\u0103 (inhibitor DPP-4)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/diabetes-medication\/\"><strong>Vizualiza\u021bi toate Medicamentele pentru Diabet<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Dezaprobare medical\u0103.<\/strong> Aceast\u0103 pagin\u0103 are scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui medic calificat. Utiliza\u021bi \u00eentotdeauna agonii\u0219tii PPAR sub supraveghere medical\u0103 cu monitorizarea func\u021biei hepatice.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tegrital\/\">Tegrital 100 mg masticabil (Carbamazepin\u0103) \u2014 Neuralgie trigeminal\u0103 \u0219i crize epileptice<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/sertafine\/\">Sertafine<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/wysolone\/\">Wysolone<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/leetrexate\/\">Leetrexate<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/novonorm\/\">Novonorm<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Regleaz\u0103 nivelul lipidelor<br \/>\n\u2705 Controlizeaz\u0103 glicemia<br \/>\n\u2705 Reduce riscul cardiovascular<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te sensibilitatea la insulin\u0103<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te s\u0103n\u0103tatea metabolic\u0103<\/p>\n<p>Lipaglyn con\u021bine Saroglitazar.<\/p>","protected":false},"featured_media":59204,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[4645,4646],"class_list":{"0":"post-59203","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-lipaglyn","11":"product_tag-saroglitazar","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/59203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=59203"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/59204"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=59203"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=59203"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=59203"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=59203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}